Health
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies – PRNewswire
/PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the…
NEW BRUNSWICK, N.J., July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and provi…
-
General9 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News19 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News11 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
General23 hours agoDr Daniel Hunt, Michael Long and Christine Anu celebrated at 50th NAIDOC Week Awards